In a 14-year-old female with major depressive disorder, generalized anxiety disorder, insomnia, possible obsessive‑compulsive disorder, who is on escitalopram (Lexapro) 20 mg and reports worsening mood during the mid‑to‑late luteal phase of her menstrual cycle, what additional diagnosis should be considered?

Premenstrual Dysphoric Disorder (PMDD)

Based on the clear temporal relationship between mood worsening and the mid-to-late luteal phase of her menstrual cycle, this patient should be evaluated for Premenstrual Dysphoric Disorder (PMDD) as an additional diagnosis.

Clinical Reasoning

This 14-year-old presents with a critical diagnostic clue: her mood consistently worsens during the "mid-to-late portion of her menstrual cycle, particularly around the later twenties of her cycle." This luteal-phase pattern—combined with her lack of response to escitalopram 20 mg despite adequate trial duration—strongly suggests PMDD rather than treatment-resistant MDD alone.

Key Diagnostic Features Present:

• Temporal pattern: Mood deterioration specifically during the late luteal phase (days 20-28 of cycle)
• Baseline depression: High depressive baseline that cyclically worsens
• Treatment resistance: Minimal improvement despite therapeutic SSRI dosing for adequate duration
• Age and sex: 14-year-old female with established menstrual cycles

The patient was appropriately encouraged to track mood symptoms in relation to her menstrual cycle—this prospective charting is essential for confirming PMDD diagnosis, as symptoms must demonstrate clear luteal-phase onset and follicular-phase remission 1.

Distinguishing PMDD from Treatment-Resistant MDD

PMDD represents a distinct diagnostic entity that can coexist with MDD but requires different management considerations. While escitalopram is effective for both conditions 2, 3, 4, the dosing strategy and timing may need adjustment for PMDD. The FDA-approved dose range for escitalopram in adolescents with MDD is 10-20 mg daily 2, which this patient has reached without adequate response.

Critical Diagnostic Steps:

1. Prospective daily symptom tracking for at least two menstrual cycles documenting:

   • Mood symptoms (depression, irritability, anxiety)
   • Physical symptoms (bloating, breast tenderness, fatigue)
   • Functional impairment
   • Clear luteal-phase worsening with follicular-phase improvement

2. Rule out pure menstrual exacerbation of MDD: In PMDD, there should be relative symptom-free intervals during the follicular phase, whereas this patient reports "depression remaining at a high baseline"—suggesting possible comorbid MDD and PMDD

3. Assess for other contributors: The pending laboratory work is appropriate to evaluate thyroid function, vitamin D levels (which she's already supplementing), and potentially iron studies given her age and menstrual status

Management Implications

If PMDD is confirmed, treatment modifications should be considered:

• Continuous SSRI dosing (current approach) versus luteal-phase-only dosing (days 14-28 of cycle)
• Dose optimization: Some patients with PMDD require higher SSRI doses than typically used for MDD
• Augmentation strategies: Hormonal contraceptives with continuous dosing to eliminate hormonal fluctuations may be beneficial
• Non-pharmacologic interventions: Calcium supplementation (1200 mg daily), regular aerobic exercise, and cognitive-behavioral therapy specifically targeting PMDD symptoms

Important Safety Considerations:

Given her history of passive suicidal ideation and current age (14 years), close monitoring remains essential. Escitalopram carries a black box warning for treatment-emergent suicidality in adolescents 2. The patient should be assessed at regular intervals—ideally within 1-2 weeks of any medication changes 5, 6.

Watch for treatment-emergent mania/hypomania, particularly at the current 20 mg dose, as case reports document dose-related mood switching with escitalopram 7, 8. Her report of "no noticeable improvement" rather than mood elevation is reassuring, but ongoing monitoring is warranted.

Addressing the Insomnia Component

Her persistent sleep-onset insomnia "despite feeling physically exhausted" without racing thoughts suggests this may be a distinct symptom requiring targeted intervention rather than purely anxiety-driven. Consider:

• Sleep hygiene optimization as first-line
• Melatonin or ramelteon if behavioral interventions fail 9
• Avoid sedating antidepressants like mirtazapine or trazodone initially, as adding another medication increases complexity in an adolescent already on escitalopram

The OCD Question

The "possible OCD" in her history requires clarification. True OCD requires obsessions and/or compulsions that are time-consuming (>1 hour daily) and cause significant distress or functional impairment 10. Her "slight reduction in ruminative thoughts" with escitalopram suggests these may represent anxious ruminations (part of GAD) rather than true obsessions. If OCD is confirmed, escitalopram 20 mg is within the therapeutic range, though OCD often requires higher SSRI doses (up to 40 mg escitalopram equivalent) 10.

The primary diagnostic consideration at this juncture is PMDD, which would explain her treatment resistance pattern and provide a clear therapeutic target through prospective symptom tracking and potential treatment modification.